New Zealand markets closed

Prime Medicine, Inc. (PRME)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.14-0.19 (-3.56%)
At close: 04:00PM EDT
5.14 0.00 (0.00%)
After hours: 05:42PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 616.96M
Enterprise value 450.03M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)824.66
Price/book (mrq)2.53
Enterprise value/revenue 761.47
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-64.55%
S&P500 52-week change 322.55%
52-week high 315.75
52-week low 34.11
50-day moving average 36.12
200-day moving average 37.37

Share statistics

Avg vol (3-month) 3950.89k
Avg vol (10-day) 31.25M
Shares outstanding 5120.03M
Implied shares outstanding 6120.03M
Float 851.71M
% held by insiders 126.27%
% held by institutions 166.07%
Shares short (14 Jun 2024) 411.57M
Short ratio (14 Jun 2024) 412.2
Short % of float (14 Jun 2024) 420.25%
Short % of shares outstanding (14 Jun 2024) 49.64%
Shares short (prior month 15 May 2024) 411.25M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-8,179.53%

Management effectiveness

Return on assets (ttm)-39.71%
Return on equity (ttm)-78.27%

Income statement

Revenue (ttm)591k
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -194.68M
Net income avi to common (ttm)-204.5M
Diluted EPS (ttm)-2.18
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)210.72M
Total cash per share (mrq)1.82
Total debt (mrq)43.79M
Total debt/equity (mrq)17.97%
Current ratio (mrq)8.90
Book value per share (mrq)2.11

Cash flow statement

Operating cash flow (ttm)-191.56M
Levered free cash flow (ttm)-109.17M